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Percutaneous transluminal angioplasty (PTA) is
one therapeutic modality for the treatment of focal
occlusive disease of the superficial femoral artery
(SFA) and the popliteal artery. Compared with sur-
gical revascularization, it is less invasive, is less cost-
ly, and has a low incidence of complications.1-8
Initial technical success rates of 90% to 95% have
been achieved for stenotic lesions and of 80% to 95%
for complete occlusions.3,4,6,7
Because of inconsistent reporting standards, the
efficacy of femoropopliteal PTA remains controver-
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sial. Cumulative patency rates of 40% to 80% over 1
to 5 years have been reported.3-8 The wide variabil-
ity among the published results is due to differences
in the criteria used to denote success and is due to
differences in patient demographics and the types of
lesions treated.
The primary goal of treatment is to achieve clini-
cal success as measured by an improvement in walking
distance, the resolution of rest pain, or limb salvage.
Despite technical success and acceptable anatomic
patency after PTA, improvement in clinical status is
not always achieved.3,9,10 The purpose of this report
was to determine the clinical success and cumulative
anatomic patency rates of femoropopliteal PTA per-
formed by vascular surgeons at our institution and to
determine the etiology of clinical failure. The out-
come of clinical failure and the role of supplemental
endovascular procedures to treat clinical failure were
also evaluated.
METHODS
The records of all patients who underwent PTA
of the femoropopliteal arterial segment by our vas-
cular group since 1992 were reviewed. Repeat
dilatations at sites previously treated with PTA were
combined with primary PTA because the outcome is
identical.4,7,11-15 Only patients with complete
records and at least one postprocedure clinical and
anatomic assessment within the same 30-day interval
were included. Patients who had undergone laser-
assisted balloon angioplasty, atherectomy, and
thrombolysis were excluded.
Risk factors, clinical symptoms, and the preproce-
dure resting ankle/brachial index (ABI) were noted
in each patient. Diagnostic angiography was per-
formed before intervention. The location and degree
of each treated lesion and the runoff status were
recorded. Simultaneous unilateral interventions were
reported as separate lesions if they occurred in sepa-
rate vascular beds (SFA vs popliteal artery).
Antegrade puncture was used to access the
femoropopliteal lesion in most patients. Angioplasty
procedures were performed using low-profile, high-
pressure balloons equal to the diameter of the adja-
cent, normal arterial segment. All patients were
given 5000 units of intravenous heparin before the
PTA. Balloon inflation was performed for 30 to 60
seconds at pressures of 6 to 12 atm. Inflation was
repeated twice and followed by angiographic assess-
ment of the result. If a residual stenosis > 30% was
present, angioplasty was repeated with a larger bal-
loon. Selective stent placement was performed for a
residual stenosis > 30% or a flow-limiting dissection.
Primary stenting was not performed. Unless con-
traindicated, all patients were treated with aspirin. A
full-dose of warfarin sodium (Coumadin) was
administered if a stent was deployed.
Success, patency, and failure were defined accord-
ing to the Society for Vascular Surgery/International
Table I. Characteristics of femoropopliteal lesions
that underwent PTA (n = 112)
Location of lesion
SFA 84 (75%)




Average degree of stenosis (%) 80 ± 16
Length of stenosis
< 2 cm 81 (72%)
> 2–5 cm 22 (20%)
> 5–10 cm 9 (8%)
Runoff status
Good (2-3 vessels) 69 (62%)
Poor (0-1 vessel) 43 (38%)




Society for Cardiovascular Society Ad Hoc
Subcommittee on Reporting Standards for
Endovascular Procedures.16 Technical failure was
defined as the inability to cross the lesion with a
guidewire leading to termination of the procedure and
was considered an immediate clinical and anatomic
failure. Immediate anatomic success was defined as a
residual stenosis < 30% at the completion of the pro-
cedure. A residual stenosis > 30% or flow-limiting dis-
section after PTA successfully treated with immediate
stent deployment was not considered an immediate
anatomic failure. All patients underwent at least one
postprocedure clinical and anatomic assessment within
the same 30-day interval. Our routine surveillance
protocol includes a clinical evaluation, an ABI, and a
color-flow duplex scan (CDS) at 24 hours, 1 month, 6
months, and 1 year after the procedure and then at
yearly intervals. Clinical success was defined as
improvement in walking distance that was greater than
50% in claudicants, resolution of ischemic rest pain, or
limb salvage in patients with tissue loss. Assessment of
walking distance and rest pain was determined by
patient interview. Intermediate and long-term
anatomic patency were defined as a restenosis < 50% at
the site of PTA, which was assessed by angiography or
CDS. In our vascular laboratory, a diameter reduction
greater than 50% corresponds to a doubling of the
peak systolic velocity across the stenotic segment as
compared with the adjacent normal arterial segment.
Cumulative clinical success and anatomic paten-
cy were calculated for each lesion according to life
table analysis on an intent-to-treat basis. Patients
who failed clinically during the follow-up period
were subjected to further review. The etiology of
clinical failure was determined by anatomic informa-
tion obtained with angiography and/or CDS. The
management of clinical failures was also evaluated.
RESULTS
Since 1992, 98 patients underwent PTA of the
SFA or popliteal artery. Thirteen patients were
excluded because of incomplete records. There were
no technical failures among the excluded patients.
There were 41 male and 44 female patients with an
average age of 56 years (range, 35-88 years) who
met inclusion criteria. Risk factors included smoking
(71%), hypertension (68%), diabetes mellitus (40%),
and hyperlipidemia (26%).
In 85 patients, 112 distinct lesions were treated.
Twelve lesions were sites of previous PTA.
Indications for treatment were claudication (59%),
rest pain (19%), tissue loss (17%), and prophylaxis
for stenoses proximal or distal to bypass grafts (5%).
Claudication occurred at one-half block in 60%, one
block in 38%, and two blocks in 2%. The mean pre-
procedure resting ABI was 0.66 (range, 0.18-1.05).
Lesion characteristics are listed in Table I. Most
lesions were located in the SFA. Most were stenoses
less than 2 cm in length with good distal runoff.
Technical failure occurred in six (5.4%) of 112
lesions. Inability to cross the lesion with a guidewire
was the cause of technical failure in one case and was
considered both an immediate clinical and anatomic
failure. In three cases, a residual stenosis > 30% was
present after PTA, and in two cases, a flow-limiting
dissection occurred. All five were successfully treated
with stent deployment across the lesion and were
therefore not considered immediate anatomic fail-
ures.
There were no procedural mortalities. Distal
embolization to the anterior tibial artery occurred in
one case and was resolved with catheter-directed
thrombolysis. There were no cases of arterial rupture
or acute arterial occlusion.
Cumulative clinical success was 69% at 1 year,
54% at 2 years, 49% at 3 years, and 40% at 4 years
(Table II, Figure). Cumulative anatomic patency
was 74% at 1 year, 62% at 2 years, 57% at 3 years, and
52% at 4 years (Table III, Figure). All patients
underwent CDS so that anatomic patency could be
assessed, and 53% also underwent angiography.
There were 45 cases of clinical failure after PTA.
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Table II. Life-table analysis of clinical success after PTA of the femoropopliteal arterial segment
Interval No. at risk No. of No. withdrawn Interval Interval Cumulative
(mo) at start of interval failures successfully failure rate (%) success rate (%) success (%) SE (%)
0-1 112 2 2 1.8 98.2 98.2 1.2
1-6 108 20 17 20.1 79.9 78.5 3.5
6-12 71 8 11 12.2 87.8 68.9 4.6
12-24 52 9 18 20.9 79.1 54.5 5.1
24-36 25 2 7 9.3 90.7 49.4 7.0
36-48 16 2 9 17.4 82.6 40.8 7.8
48-60 5 0 3 0 100.0 40.8 14.0
> 60 2 2 0 100.0 0 0 0
Of the clinical failures, twenty-seven (60%) occurred
in conjunction with anatomic failure at the PTA site,
and eighteen (40%) occurred despite anatomic
patency at the PTA site. The etiology for clinical fail-
ure is shown in Table IV. When clinical failure
occurred in conjunction with anatomic failure at the
PTA site, the most common cause was restenosis
(44%), followed by occlusion at the PTA site (30%).
When clinical failure occurred despite maintained
anatomic patency at the PTA site, most failures were
due to progression of disease at a site remote from
the original PTA site but within the femoropopliteal
segment (67%). The average time to clinical failure
was 11.8 months (range, 0-61 months) when asso-
ciated with anatomic failure and 15.2 months
(range, 0-69 months) when associated with anatom-
ic patency.
The management of clinical failures included
observation, surgical bypass graft, and PTA (Table
V). Supplemental PTA was performed in 50% of all
clinical failures to treat recurrent stenoses or occlu-
sions and to treat new femoropopliteal or iliac artery
disease. Of the 12 restenoses, three were successful-
ly redilated with PTA alone. Three required stent
placement after PTA, two for a residual stenosis >
30% and one for a flow-limiting dissection. Of the
eight reocclusions, three were successfully dilated
with PTA alone, and two required selective stent
placement, one for a residual stenosis > 30% and one
for a flow-limiting dissection. Of the stents
deployed, two were Palmaz stents (one in the SFA
and one in the above-knee popliteal artery), and
three were Wallstents (all in the SFA). Fifty percent
of new femoropopliteal arterial segment disease was
amenable to repeat PTA. All new iliac disease was
treated percutaneously.
Surgical bypass graft was used to treat 37% of
clinical failures. The nature of the surgical bypass
graft was unchanged by the preceding PTA. Only
one patient in our series of 85 patients had limb loss
after PTA. This patient, treated for critical ischemia,
required below-knee amputation after clinical failure
following PTA and a failed surgical bypass graft.
DISCUSSION
Although PTA has become the treatment of
choice for focal iliac occlusive disease, its role in
infrainguinal disease remains unclear because of the
variable success rates reported in the literature. The
reported outcomes are variable because of differ-
ences in the criteria used to denote success and
because of differences in the patient populations and
the lesions treated.
Multiple factors have been shown to affect the
results of femoropopliteal PTA. Patients with dia-
betes have worse outcomes than patients without
diabetes.3,4 Patients treated for critical ischemia have
lower patency rates than patients treated for claudi-
cation.4,6,10 Stenoses are associated with better
patency than occlusions,4-6,8 but the patency rates
can be similar if initial technical failures are exclud-
ed.4 Concentric lesions have been found to be more
favorable than eccentric lesions,4,7 and focal stenoses
fare better than long-segment lesions.2-4,7 In most
studies, poor runoff correlates with worse out-
comes.5,7 A residual stenosis > 30% at the time of the
procedure decreases the patency rate, whereas a
focal, nonoccluding dissection does not appear to
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Table III. Life table analysis of anatomic patency after PTA of the femoropopliteal arterial segment
Interval No. at risk at No. of No. withdrawn Interval failure Interval patency Cumulative
(mo) start of interval failures patent rate (%) rate (%) patency (%) SE (%)
0-1 112 3 10 2.8 97.2 97.2 1.5
1-6 99 17 13 18.4 81.6 79.3 3.6
6-12 69 4 12 6.3 93.6 74.3 4.5
12-24 53 7 20 16.3 83.7 62.2 5.2
24-36 26 2 8 9.1 90.9 56.5 7.3
36-48 16 1 7 8.0 92.0 52.0 9.0
48-60 8 0 4 0 100.0 52.0 12.7
> 60 4 3 1 85.7 14.3 7.4 3.6
Table IV. Etiology of clinical failure after PTA of
the femoropopliteal arterial segment (n = 45)
Clinical failure with anatomic failure (27)
Restenosis 12 (44%)
Occlusion 8 (30%)
Restenosis and new femoropopliteal disease 6 (22%)
Technical failure 1 (4%)
Clinical failure despite anatomic patency (18)
New femoropopliteal disease 12 (67%)
Iliac disease 3 (17%)
Tibial disease 2 (11%)
Bypass graft failure 1 (5%)
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affect long-term prognosis.4
Primary stenting has not been shown to improve
outcome compared with PTA alone.17 However,
selective stent placement for a residual stenosis >
30% or a flow-limiting dissection after PTA has
shown acceptable patency rates of up to 65% at 4
years.11,12
Patency after PTA appears to be highest in
patients with claudication who have focal stenoses
and good runoff.2,4-7 In this population, 5-year
patency rates as high as 68% have been achieved.2
Several authors have advocated angioplasty over sur-
gical revascularization in such patients.2,18 In one
analysis of 26 published studies, angioplasty was pre-
ferred to surgery for patients with claudication. Even
patients with critical ischemia and a stenosis (rather
than occlusion) who underwent PTA fared better in
terms of complication rates, outcomes, and cost
compared with surgical bypass graft.2 In our series of
patients, which included patients with rest pain and
ischemic tissue loss, anatomic patency rates of 74% at
1 year, 62% at 2 years, 57% at 3 years, and 52% at 4
years were achieved. These results are comparable to
those reported in the literature.3-8 Although we
attempted to further classify our anatomic results
according to lesion characteristics and indications for
treatment, our data were too small for meaningful
analysis. We tended to treat lesions that have been
shown to respond favorably to PTA, on the basis of
our previous experience with laser-assisted balloon
angioplasty and the current literature.
Uniformity in reporting standards must be
accomplished to better define the results of PTA.
The Society for Vascular Surgery/International
Society for Cardiovascular Surgery Subcommittee
on Reporting Standards for Endovascular
Procedures advocates that three criteria—sympto-
matic improvement, ABI improvement, and
anatomic patency at the treated site—be present for
the PTA procedure to be considered successful.16
However, this recommendation is not ideal.
Anatomic patency, with which the durability of the
PTA procedure is measured, is not always associated
with clinical and hemodynamic improvement.9,19
Up to 17% of anatomically successful PTA sites will
show no improvement in ABI, mostly because of
distal multisegmental disease.9 In another series of
patients undergoing infrainguinal PTA for limb-
threatening ischemia, less than 40% were observed
to have hemodynamic improvement.10 Resting ABIs
are inaccurate predictors of restenosis at PTA
sites.9,14 In one group of patients, a 74% patency
rate was found using a 0.15 improvement in the
resting ABI as the sole criterion for success, but the
actual anatomic patency was only 31% when these
patients underwent angiography.14 Exercise ABIs
may be more accurate. However, not all patients can
exercise, and the results are difficult to standardize.
In addition, a hemodynamic deterioration cannot
distinguish recurrent stenosis from new disease.
Therefore, the requirement that hemodynamic suc-
cess be achieved may underestimate the effectiveness
of PTA.
We believe that clinical success is the most
important outcome measure because the primary
goal of therapy is to improve clinical symptoms.
Anatomic patency at the PTA site is irrelevant if
symptomatic improvement is not achieved. We ana-
lyzed our anatomic results using CDS and angiog-
raphy to confirm that our ability to perform the
procedure and our anatomic patency rates were
comparable to other published reports, but our pri-
mary objective was to evaluate the clinical outcome
of these procedures. We have achieved clinical suc-
cess rates of 69% at 1 year, 54% at 2 years, 49% at 3
years, and 41% at 4 years. These are comparable to
clinical success rates reported in the literature.19 We
have shown that although most clinical failures
Table V. Management of clinical failure after PTA of the femoropopliteal arterial segment
PTA Bypass graft Observation
Clinical failure with anatomic failure (27)
Restenosis (12) 6 5 1
Occlusion (8) 5 1 2
Restenosis and new femoropopliteal disease (6) 2 3 1
Technical failure (1) 0 1 0
Clinical failure despite anatomic patency (18)
New femoropopliteal disease (12) 6 5 1
Iliac disease (3) 3 0 0
Tibial disease (2) 0 1 1
Bypass graft failure (1) 0 1 0
Total 22 (49%) 17 (38%) 6 (13%)
occurred in conjunction with anatomic failure at the
PTA site, a significant number of clinical failures
occurred despite maintained anatomic patency at
the PTA site. Therefore, anatomic patency does not
guarantee clinical success.
In those patients with clinical failure in conjunc-
tion with anatomic failure at the PTA site, most fail-
ures occurred within the first year after treatment,
which is consistent with other published
reports.4,7,20 Restenosis was the most common
anatomic cause associated with clinical failure in this
group (44%). Most recurrent lesions reported in the
literature are due to restenosis rather than occlusion,
even in lesions that were originally occlusions.7 In
addition, 22% of our patients with anatomic failure
at the PTA site also had progression of disease
remote from the PTA site but within the
femoropopliteal segment. A femoropopliteal bypass
graft was required in 50% of these patients because
of the diffuse nature of the disease. However, we
were able to perform supplemental PTA procedures
in 48% of anatomic failures, all with immediate
anatomic success. Because of the small number of
secondary PTA procedures, we were not able to per-
form meaningful life table analyses of the clinical and
anatomic success of these secondary procedures.
However, several studies have demonstrated that
secondary PTA procedures, even within a stent, are
safe and associated with long-term success rates that
are comparable to the primary procedure.4,7,11-15 In
our series, when surgical bypass graft was required,
the nature of the bypass graft was unchanged by the
preceding PTA. Previous reports have shown that
repeat PTA does not alter the nature of subsequent
arterial reconstruction.4,7,13-15
Despite anatomic patency, clinical failure
occurred in 40% of our patients. Except for one case
of a bypass graft failure distal to the PTA site, all of
these clinical failures were due to progression of dis-
ease, most commonly within the femoropopliteal
segment (67%). Nearly all new sites of disease
occurred in areas of previously normal arteries or in
arterial segments with previously minimal-mild dis-
ease (< 50% stenosis). New lesions tended to occur
later than restenoses, usually after the first year after
treatment, which is consistent with other reports.20
Diffuse disease of the femoropopliteal arterial seg-
ment was treated with femoropopliteal artery bypass
graft, whereas new, focal disease was amenable to
PTA. New iliac lesions were the cause of clinical fail-
ure in 17% of patients, all of whom were treated with
PTA. New tibial disease occurred in 11% of patients,
one of whom underwent surgical bypass graft and
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one of whom was observed. Overall, 50% of the clin-
ical failures with maintained patency at the PTA site
were amenable to supplemental PTA of new
femoropopliteal or iliac lesions.
The ability to manage clinical failures percuta-
neously, either with redilatation of the prior PTA site
or with dilatation of new areas of disease stresses the
importance of close clinical follow-up and CDS sur-
veillance. Restenosis after PTA is most often due to
myointimal hyperplasia and may progress to occlu-
sion because of superimposed thrombus forma-
tion.20 Surveillance using CDS can detect recurrent
stenoses before progression to complete occlusion
occurs. The technical failure rate is higher, and the
anatomic patency rates are lower in cases of com-
plete occlusion.4,6-8 New lesions detected within the
femoropopliteal segment or proximally within the
iliac system may also be treated percutaneously and
can be detected with serial CDS evaluations.
According to our anatomic patency data, a CDS on
the day after PTA is unnecessary because all anatom-
ic failures within the first month were immediate
failures at the time of the procedure. We recom-
mend follow-up evaluation at 1 month, 6 months,
and 12 months after the initial PTA and then at year-
ly intervals.
There are several limitations to our study. Our
clinical assessment of walking distance in claudicants
is based on patient interview, which may be inaccu-
rate. We do not routinely use treadmill ABI testing
unless the patient has symptoms of claudication
despite a normal-resting ABI. To evaluate all
patients solely to determine absolute walking dis-
tance is costly and time-consuming. However, this
approach would have been more objective. In addi-
tion, we do not have information regarding subse-
quent procedures in patients who were lost to fol-
low-up. We have made no effort to contact these
patients because without direct clinical evaluation,
we would only be able to assess their clinical status
and be unable to assess their anatomic patency.
Subsequently, we did not believe that any useful
information for this particular manuscript could be
obtained by attempting to contact this patient sub-
group. Nevertheless, at a 4-year follow-up, we have
meaningful life table data of clinical and anatomic
results with an SE less than 10%. There was no sig-
nificant difference in our results when we analyzed
our data based on lesions versus patients.
As shown by the relatively small number of
patients treated with PTA of the femoropopliteal
arterial segment over a 7-year interval, we have
maintained a fairly conservative approach.
Modification of risk factors and a walking program
trial in claudicants are our first-line therapy.
However, when this approach is not successful and
patients have lifestyle-limiting claudication, rest
pain, or tissue loss, an angiogram is performed.
Focal disease that has been shown to respond favor-
ably to PTA is generally treated percutaneously.
Multilevel arterial segment disease, most often pre-
sent in patients with critical ischemia, has been
shown to respond poorly to treatment of only the
proximal SFA or popliteal disease.10 Occasionally,
patients with tissue loss who had one-vessel runoff in
continuity with the femoropopliteal lesion were
treated in this study. Of these patients, 75% had sin-
gle-vessel runoff, yet 66% of this group achieved
clinical success or wound healing. The remaining
34% who failed clinically failed because of restenosis
or occlusion at the PTA site, not because of pro-
gression of disease. The other patients with tissue
loss who had two- or three-vessel runoff all achieved
clinical success with femoropopliteal PTA. When we
further evaluated the 18 patients who failed clinical-
ly despite anatomic patency at the PTA site, we
found that 15 patients (83%) were treated for clau-
dication, two (11%) for rest pain, and one (1.8%) for
a stenosis proximal to a bypass graft. Fifty percent
had three-vessel runoff, 28% had two-vessel runoff,
and 39% had one-vessel runoff. We do not believe
that multilevel disease, present at the time of PTA,
was responsible for early clinical failure in these
patients with maintained patency of the PTA site
because the new disease occurred in areas of previ-
ously minimal-mild (< 50% stenosis) disease. In
addition, we believe that after a walking program
trial and risk factor modification, femoropopliteal
PTA is an appropriate treatment option, other than
observation alone, in patients with claudication and
poor runoff. The performance of an infrageniculate
bypass graft in a patient with claudication seems
excessive.
In conclusion, we have shown that PTA is an
acceptable therapeutic option for the treatment of
short-segment disease of the SFA and popliteal
artery. Although primary clinical success rates were
inferior to surgical revascularization, supplemental
PTA was possible in 50% of patients. Repeat percu-
taneous treatment may extend the interval of clinical
success and may obviate the need for surgical bypass
graft. Only with careful surveillance of the PTA site
and adjoining arterial segments will the natural his-
tory of percutaneously treated SFA and popliteal
artery be elucidated and recurrent or new lesions be
detected. An understanding of the relationship
between clinical and anatomic success will help
determine the optimal treatment of femoropopliteal
occlusive disease.
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have clinical success. Second, any report espousing the
virtues of a procedure should probably include the com-
plications of that procedure. Would you enlighten us as to
your procedural complications?
Dr Karch. We did not perform a multivariate analysis.
The objective of our paper was to determine the etiology
and outcome of clinical failure following PTA. We did not
analyze anatomic patency separately to determine the rela-
tionship of patency and lesion characteristics, runoff sta-
tus, and patient demographics. However, there is exten-
sive literature showing that stenoses have a better patency
rate than occlusions, focal disease has a better outcome
than long-segment disease, and more proximal lesions in
the SFA do better than more distal SFA lesions and
popliteal lesions. We did not look at these individual fac-
tors in our patient population.
In terms of our complication rate, distal embolization
to the anterior tibial artery occurred in one patient and
was successfully treated with catheter-directed urokinase
infusion. There were no procedural mortalities, acute arte-
rial occlusions, or arterial ruptures.
Dr Minion (Lexington, Ky). One quick question. You
broke down your indications. I was wondering, did you
find a difference in your clinical results for the groups with
different indications? We have done a handful of these
procedures. All of them have been for tissue loss, and I am
still waiting for those ulcers to heal. I do not think we have
seen a success for tissue loss with angioplasty.
Dr Karch. We performed the majority of procedures on
patients with claudication and rest pain. We did not strat-
ify our results based on the indication for the procedure
since the data were small. I agree that patients with multi-
level arterial segment disease, most often present in
patients with critical ischemia, respond poorly to treat-
ment of only the proximal SFA of popliteal disease.
However, occasionally, we treated patients with tissue loss
who had one-vessel runoff in continuity with the
femoropopliteal lesion. Of these patients, 66% achieved
wound healing. The remaining 34% who failed clinically
failed because of restenosis or occlusion at the PTA site,
not because of progression of disease. The other patients
with tissue loss who had two- or three-vessel runoff all
achieved clinical success with femoropopliteal PTA.
DISCUSSION
Dr Cambria (Milwaukee, Wis). Could you break down
for us the indication for interventions in your patients?
And, in order to claim clinical success in the endovascular
reporting standards, you have to have an improvement in
ABI. Could you break down your ABI results as well?
Dr Karch. To answer your first question, about 60% of
patients were treated for disabling claudication, 20% for
rest pain, and the remainder for tissue loss. The main
problem with the reporting standards is that for each
lesion, success can be based on clinical improvement,
hemodynamic or ABI improvement, or maintained
anatomic patency. Dr Ahn’s paper regarding the
SVS/ISCVS Ad Hoc Subcommittee on Reporting
Standards for Endovascular Procedures requires that all
three of these criteria be fulfilled to denote success.
However, there have been several studies that have shown
that ABI results may be misleading, especially in the pres-
ence of more diffuse disease. Our average pre-PTA ABI
was 0.66. We chose not to evaluate our results based on
ABI since the goal of our study was to evaluate our clini-
cal success and how that related to anatomic patency.
Dr Mansour (Maywood, Ill). That was a very nice
paper, Dr Karch. I have two questions for you. The first
one is whether there was any difference in the results fol-
lowing treatment of above-knee popliteal versus below-
knee popliteal lesions. The second question relates to the
number of lesions you dilated. You had 85 patients and
112 lesions. Do the patients that have more than one
lesion dilated present with clinical failure more often than
those that had single lesions?
Dr Karch. To answer your first question, the majority of
our lesions were in the superficial femoral artery. Only 25%
were in the popliteal artery, and therefore, the numbers
were too small for meaningful life table analysis if broken
down into the above-knee and below-knee location. Of the
45 clinical failures, 10 (22%) occurred following PTA of
the popliteal artery. In addition, the clinical failure rate was
the same in patients who underwent PTA of a single lesion
and those who underwent multiple procedures.
Dr Schwartz (Chicago, Ill). I, too, enjoyed your pre-
sentation. Did you perform multivariate analysis to try to
help us figure out which patients are good for this proce-
dure? We would like to be able to predict which ones will
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Dr Slesh (Willoughby, Ohio). With 60% of your
patients being claudicants and an average preprocedural
ABI of 0.6, it seems to me that your results are probably
not as good as the natural history of the disease. And I do
not know what disabling claudication is.
Dr Karch. Our first-line therapy in claudicants is modi-
fication of risk factors, smoking cessation, and a walking
program. When this fails and the patient has lifestyle-lim-
iting or disabling claudication and requests treatment, we
proceed with angiography to determine whether PTA or
surgical bypass are appropriate therapeutic options.
Dr Whitehouse (Ann Arbo, Mich). I have one other
question for you. You described focal superficial femoral
artery stenosis, and yet a focal stenosis may occur in a rel-
atively undiseased vessel or a vessel with a fair amount of
associated nonfocal disease. How aggressive are you will-
ing to be? How disease-free does the rest of the SFA have
to be for you to be willing to dilate the focal stenosis?
Dr. Karch. If a high-grade focal stenosis is present in
association with mild nonfocal disease, I would treat the
high-grade lesion with PTA. PTA is a low-risk procedure
and does not “burn any bridges” since anatomic failure
may be amenable to repeat PTA. We have also found that
when surgical bypass is needed to treat clinical failure fol-
lowing PTA, the nature of the surgical bypass is
unchanged by the preceding PTA. This has also been doc-
umented in the literature.
